抗p200类天疱疮
抗p200类天疱疮是1996年首次描述的自身免疫性大疱病,临床表现类似大疱性类天疱疮或炎症型获得性大疱性表皮松解症,约40%病例有黏膜受累。血清自身抗体识别真皮表皮交界处200 kDa蛋白,后续鉴定层粘连蛋白γ1和层粘连蛋白β4为靶抗原,后者已有标准化检测体系。本文综述其流行病学、临床表现、诊断、靶抗原、病理生理和治疗。
要点
- 抗p200类天疱疮临床表现类似大疱性类天疱疮,约40%有黏膜受累,易误诊。
- 血清自身抗体识别200 kDa蛋白,靶抗原包括层粘连蛋白γ1和层粘连蛋白β4。
- 层粘连蛋白β4的标准化检测已广泛应用,可在专科中心外诊断该病。
核心结论
- 抗p200类天疱疮是自身免疫性大疱病,层粘连蛋白β4是病理生理相关自身抗原,但体内功能相关性数据仍缺乏。
研究设计与样本
- 综述,总结抗p200类天疱疮的流行病学、临床表现、诊断、靶抗原、病理生理和治疗。
主要发现
- 临床表现为紧张性水疱、糜烂、结痂和红斑/斑块,约40%病例有黏膜受累。
- 血清自身抗体识别真皮表皮交界处200 kDa蛋白,间接免疫荧光标记盐裂皮肤真皮侧。
- 层粘连蛋白γ1和层粘连蛋白β4被鉴定为靶抗原。
- 层粘连蛋白β4的标准化、高特异性和敏感性血清IgG检测体系已广泛可用。
关键数值与推荐
- 约40%病例有黏膜受累。
- 自身抗体识别200 kDa蛋白,标记盐裂皮肤真皮侧。
- 层粘连蛋白β4的标准化检测体系已广泛可用。
临床怎么用
- 层粘连蛋白β4血清IgG标准化检测可在专科中心外诊断抗p200类天疱疮。
局限性
- 缺乏体内数据阐明抗层粘连蛋白β4 IgG的功能相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-p200 pemphigoid is an autoimmune bullous disorder, first described in 1996. Clinically, it presents with tense blisters, erosions, crusts and erythematous macules/plaques, in addition to mucosal involvement in about 40% of cases, resembling bullous pemphigoid or the inflammatory variant of epidermolysis bullosa acquisita. As in other pemphigoid diseases, autoreactive IgG and/or C3 bind along the cutaneous basement membrane zone. Serum autoantibodies recognize a 200 kDa protein of the dermoepidermal junction that label the dermal side of human salt-split skin by indirect immunofluorescence microscopy. Subsequently, laminin γ1 has been described as a target antigen of anti-p200 pemphigoid. Laminin β4 has also recently been identified as a target antigen. A standardized, highly specific and sensitive detection system for serum anti-laminin β4 IgG is now widely available. This allows for the diagnosis of anti-p200 pemphigoid outside of specialized centres. Current in vitro and ex vivo data point to laminin β4 as the pathophysiologically relevant autoantigen, while in vivo data to clarify the functional relevance of anti-laminin β4 IgG are still lacking. Here, we summarize the current knowledge about the epidemiology, clinical presentation, diagnosis, target antigens, pathophysiology and treatment of this pemphigoid disease. Autoimmune blistering diseases are a type of rare skin condition. They involve antibodies directed against the structure of the skin. This review focuses on ‘anti-p200 pemphigoid’. This condition was first described in 1996. Anti-p200 pemphigoid often looks similar to other autoimmune blistering diseases. It can share both clinical signs and immunological features with other conditions. This means that anti-p200 pemphigoid can be easily misdiagnosed without specific testing. In anti-p200 pemphigoid, antibodies have a target within the skin. This target was first reported as a ‘200 kDa’ protein found in extracts of human skin. The target was then described as ‘laminin γ1’. Most recently, ‘laminin β4’ has been identified as another autoantigen. This plays a crucial role in diagnosing anti-p200 pemphigoid. It is also central in understanding its underlying mechanisms. This review article summarizes the current knowledge about anti-p200 pemphigoid. We provide an overview of the epidemiology and clinical presentation of the disease. We also discuss the diagnosis, target antigens, pathophysiology and treatment of the condition.
引用
- Kasperkiewicz M, Pigors M, Holtsche MM, et al. Anti-p200 pemphigoid. Br J Dermatol. 2026. PMID: 40853220. doi:10.1093/bjd/ljaf324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。